GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 3,728 Shares

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 3,728 shares of the company's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $76.75, for a total value of $286,124.00. Following the completion of the sale, the chief financial officer now directly owns 28,200 shares of the company's stock, valued at approximately $2,164,350. This trade represents a 11.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Stock Down 2.9 %

NASDAQ:WGS traded down $2.27 during trading hours on Wednesday, reaching $76.93. 1,156,038 shares of the stock were exchanged, compared to its average volume of 458,372. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx Holdings Corp. has a twelve month low of $1.76 and a twelve month high of $89.11. The stock has a market cap of $2.11 billion, a PE ratio of -24.74 and a beta of 2.03. The firm has a 50 day moving average of $71.26 and a 200 day moving average of $46.55.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same period in the previous year, the business earned ($0.82) EPS. The company's revenue was up 44.3% compared to the same quarter last year. On average, equities analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Driehaus Capital Management LLC bought a new position in shares of GeneDx in the 2nd quarter valued at about $11,335,000. Fred Alger Management LLC acquired a new position in GeneDx during the third quarter worth approximately $16,731,000. Divisadero Street Capital Management LP bought a new stake in GeneDx in the second quarter valued at approximately $5,886,000. Millennium Management LLC lifted its position in shares of GeneDx by 193.5% in the second quarter. Millennium Management LLC now owns 311,401 shares of the company's stock valued at $8,140,000 after buying an additional 205,318 shares during the last quarter. Finally, Raymond James & Associates acquired a new stake in shares of GeneDx in the third quarter valued at approximately $8,090,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on WGS shares. Wells Fargo & Company raised their price target on GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 30th. Craig Hallum increased their target price on GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group lifted their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, GeneDx has an average rating of "Moderate Buy" and an average price target of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.